Company ProfilePremium

NUTEX Investments Public Limited Company

Company Profile Analysis

Ticker: NUTEX.BD

ESOMAR 23 Corporate BadgeISO Certifications Badge
NUTEX Investments Public Limited Company - Company showcase

Year Founded & Workforce

1996

1 Employees

NUTEX Investments Public Limited Company logo

NUTEX Investments Public Limited Company Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

NUTEX Investments Public Limited Company Overview

NUTEX is a former Hungarian pharmaceutical research company — originally HUMET, developer of the humic/fulvic-acid trace-element preparation HUMET-R — that has transformed over the past decade into a cash-rich, operationally dormant listed investment holding company. It no longer manufactures or sells products; its sole operating revenue (HUF 0.45 M in FY2025) comes from leasing fully amortised intangible assets to a single Hungarian counterparty. Its economic value lies in a balance sheet of roughly HUF 6.1 bn (30 June 2026) composed almost entirely of cash (EUR, USD and HUF deposits), liquid Budapest-listed equities (dominated by OTP Bank), Hungarian government securities and units of an Erste euro real-estate fund, with no debt. Hungarian financial media describe it as an "empty" listed shell that could serve as a reverse-listing vehicle. Management's stated strategy is acquisitive, and since 2025 it has built a holding/acquisition subsidiary chain, but no acquisition has yet closed. The shares trade at roughly one-third of book value.


The company's own description (2025 Annual Report and H1 2026 Report)

In its FY2025 consolidated management report, NUTEX describes itself as having operated throughout 2025 essentially as a company managing its own assets, whose activity consists of managing and coordinating its assets and investments. It continued to lease out its intangible assets, invested part of its cash in liquid securities (mainly Budapest-listed shares and Hungarian government securities), and held significant EUR and USD bank deposits plus investment units of the Erste Open-ended Euro Real Estate Investment Fund. The company states that it repaid its former long-term debt in full in earlier years and that, under its acquisition strategy, it examined new acquisition opportunities during the year, none of which had been completed.

The stated corporate purpose (H1 2026 Report, Note 1) is to manage the group's assets, ensure the sustainability of group members and increase shareholder value. The strategy includes shaping the investment portfolio through new company formation or acquisitions, and possibly reorganising, selling or realising existing holdings; promoting geographic expansion of investments; and exploiting intangible assets through leasing. The company notes that its investments were historically concentrated on human-health-related businesses, but that other types of investment may also feature in its strategy.

Independent characterisation

Business-model dimensionAssessment
Revenue modelLicensing/leasing of intangible assets (100% of revenue; one Hungarian counterparty). No product, service or subscription revenue
Economic earnings modelInvestment income: fair-value gains on listed equities, dividends, interest; FX gains/losses
Value-chain positionNone in an operating sense; capital allocator / holding company
Customer typesOne related or unrelated licensee (identity not disclosed)
End-marketsEffectively Hungarian capital markets (OTP, MOL, Richter shares; Hungarian government bonds) and euro-area real estate (via Erste fund)
Revenue mix (FY2025)Licensing 100%; product 0%; service 0%; subscription 0%

NUTEX is, in substance, a listed cash-and-securities shell with an acquisition mandate. Its income statement is driven almost entirely by mark-to-market movements on its securities portfolio (above all OTP Bank shares), dividends received, and foreign-exchange revaluation of its EUR/USD deposits. Operating costs (HUF 108.9 M SG&A in FY2025) are dominated by non-cash IFRS 2 share-based payment charges linked to its Employee Share Ownership Programme (MRP), rather than by an operating business.

Interpretive note: Because the revenue line is immaterial (HUF 0.45 M), conventional revenue-based metrics (margins, EV/Sales, revenue CAGR) are not meaningful. The appropriate analytical lens is that of a closed-end holding company: net asset value (NAV), the composition and risk of the asset base, cost drag on NAV, governance and capital-allocation discipline, and the probability and quality of a transformative acquisition.

Strategy

Stated strategic themes (paraphrased from FY2025 Annual Report and H1 2026 Report)

  1. Asset stewardship and shareholder value: manage group assets, ensure sustainability of group members and increase shareholder value.

  2. Portfolio construction through acquisitions or new companies: expand the investment portfolio by founding companies or acquiring them; reorganise, sell or realise existing holdings as appropriate.

  3. Geographic expansion of investments and improvement of their markets.

  4. Exploitation of intangible assets through leasing.

  5. Preservation of the investor structure (the company repeatedly states it intends to maintain its investor structure).

  6. Sector-agnostic broadening: historically health-focused, but other investments and activities may be pursued if they serve the company's interests.

Strategic initiatives in the last 24 months

InitiativeDateDescriptionStatus
NT Asset Management Kft.Founded 27 Jan 2025Wholly owned holding subsidiary (HUF 300 M) to manage assetsCapitalised to HUF 5,218 M by Jul 2026; holds OTP shares
Asset transfers into NT AMDec 2025–May 2026HUF 1,747 M + 1,845 M + 1,323 M cash injections; OTP shares sold to NT AM (31 Mar 2026); shareholder support for transferring the Erste fund units (20 May 2026)Ongoing
NT Valoris Kft. acquisition vehicle7 Jul 2026New Kft. dedicated to acquisitions; intended later conversion to a private Zrt.; managers may take up to 5%Founded; capital increases Aug and Oct 2026
MRP expansionJan 2025–Jun 2026See Section 9.3Ongoing; ≥32 M further shares authorised
Capital-raising authorisationsApr–Jun 2026Board authorised to raise capital up to HUF 60–70 bn through 2031 (and a further authorisation window to 2036), including preference shares; issue price for ordinary shares at least the last closing priceAuthorised, unused except MRP placement
Voting-preference share programme26 Jun 2026New unlisted voting-preference shares (up to 10x votes) at 1.5x last close, with company call optionAuthorised
Treasury share authorisationsApr–Jun 2026Board may hold up to 25% of share capital in own shares for 18 months; price ceiling 1.5x book value per share (ordinary) or 10x (preference)Authorised; no purchases since last AGM
Acquisition screening2025–2026Company examined acquisition opportunities; none completedNo transaction announced

Cost programmes / ESG commitments

No cost-reduction programmes or ESG/sustainability commitments have been announced.

Medium-term targets / guidance

NUTEX provides no financial guidance and no medium-term targets. The H1 2026 report's going-concern statement says current assets cover operating costs and the group's operation is secured on the basis of its future plans.

Analyst interpretation: The scale of capital authorisations (up to HUF 70 bn versus current equity of ≈ HUF 6.1 bn) and the creation of a dedicated acquisition vehicle signal that management is preparing for a transaction that could be an order of magnitude larger than the current company — i.e., a reverse-listing or contribution-in-kind deal that would transform NUTEX. The terms of any such deal (valuation, dilution, voting structure) will determine whether existing minority shareholders benefit.

Products & Services

NUTEX currently has no commercial product or service portfolio. The catalogue below distinguishes the current asset-based "offering" from the historic product lines that some data aggregators still attribute to the company.

Current activities (single segment)

LineDescriptionCustomerStatusPricing
Intangible-asset leasingLease of intangible assets (gross book value HUF 58.6 M, fully amortised to zero)One Hungarian counterparty (not named)Active; HUF 0.45 M revenue FY2024 and FY2025—
Proprietary securities portfolioListed equities (OTP, MOL, Richter), Hungarian government bonds and discount T-billsNot applicable (own account)ActiveNot applicable
Real-estate fund unitsErste Open-ended Euro Real Estate Investment Fund units (EUR-denominated)Not applicableHUF 548.3 M at YE2025Not applicable
FX depositsSignificant EUR and USD depositsNot applicableEUR ≈ HUF 1,451 M and USD ≈ HUF 262 M at YE2025 (derived from ±10% sensitivity disclosures)Not applicable

Historic product lines (no longer operated by NUTEX)

Product / brandDescriptionLaunchStatus
HUMET-RMedicinal product containing the Humifulvát (humic/fulvic acid) active ingredient; trace-element preparation1,994The BÉT profile still lists this as the main activity, but the company's own filings describe pure asset management; no product sales in FY2024–FY2025
Enerex (dietary supplements)Supplement brand of Canada's Enerex Botanicals Ltd., in which subsidiary HUMET North America held 70.7% in 2012—Attributed by aggregators (Musaffa, Erste Market) to the former "Nutex Group"; not consolidated in any period reviewed (2023–2026)
Organic MissionHealth/cosmetics brand attributed to the former Nutex Group by aggregators—Not consolidated in the period reviewed
Former marketsAggregators list Hungary, Slovakia, UK, Canada, Taiwan, Iran, UAE, Mexico and Hong Kong—Outdated; current revenue is 100% Hungarian

Financial Narrative

Basis of preparation: FY2024–FY2025 are audited consolidated IFRS (2025 Annual Report). FY2022–FY2023 are from the 2023 Annual Report (IFRS; the company had no subsidiary in those years, so figures are effectively standalone). FY2021 figures were not available in the sources reviewed. H1 figures are unaudited.

Income statement

Note: no dividend was declared after FY2023 (AGM April 2024), FY2024 (AGM 23 April 2025) or FY2025 (AGM 28 April 2026).

Margins. Gross, operating, EBITDA and net margins are not meaningful because revenue is HUF 0.45 M; arithmetically, FY2025 net income is roughly 1,100x revenue and the operating margin is approximately -24,900%. Revenue CAGR cannot be computed over five years; FY2024–FY2025 growth is 0%.

Financial-result composition

In the FY2024 and FY2025 cash-flow statements, dividends received appear as HUF 74.9 M and HUF 70.2 M respectively; interest received is HUF 3.3 M and HUF 18.2 M. The company attributes financial income mainly to value increases in listed shares (primarily OTP) and financial expenses mainly to unrealised FX losses on year-end revaluation of foreign-currency assets.

Interim trend

H1 2026 net income of HUF 517.7 M already exceeds full-year FY2025 (HUF 494.2 M). Trailing-twelve-month (TTM) net income to 30 June 2026 is ≈ HUF 896.5 M (derived: FY2025 494.2 − H1 2025 115.4 + H1 2026 517.7).

Balance sheet

At 30 June 2026: total assets HUF 6,103.8 M; cash HUF 2,327.7 M; short-term investments HUF 3,535.5 M; current liabilities HUF 9.5 M; equity HUF 6,094.3 M (of which attributable to parent HUF 6,090.8 M); no debt.

Asset composition at 31 December 2025

Between YE2024 and YE2025, Level 1 equity holdings rose from HUF 1,463.0 M to HUF 2,325.0 M while government securities fell from HUF 839.4 M to HUF 247.3 M — a deliberate rotation from sovereign debt into equities (largely OTP) that raised portfolio risk materially. MOL holdings were HUF 55.3 M at YE2023 (2023 Annual Report).

Cash flow

H1 2026: operating cash flow HUF -0.05 M; investing cash flow HUF +74.2 M (dividends HUF 73.6 M, interest HUF 1.0 M, capex HUF -0.4 M); financing HUF 0; net change in cash HUF +74.2 M. Operating cash flow is distorted because purchases/sales of trading securities run through working-capital lines ("other current assets").

Ratios

ROIC, net debt/EBITDA and interest coverage are not meaningful (negative EBITDA, no invested operating capital, no interest expense). The cash conversion cycle is not applicable (no inventory; trade receivables HUF 0 at YE2025). The H1 2026 report shows liabilities/equity of 0.16% and pre-tax profit/equity of 8.50% for the half-year.

Per-share and NAV metrics

Discrepancy note: Világgazdaság (January 2026), citing BÉT data, reported equity per share "above HUF 31"; the derived figures above (HUF 33.5–35.6) are higher. The difference likely reflects whether MRP-held shares are excluded and which reporting date is used. Note also that the 2025 Annual Report shows the 2024 weighted average share count as 149,046,381 in one table and 146,046,381 in another — an internal inconsistency in the filing.

Commentary on trends, inflections and drivers

Earnings are a function of the OTP share price, not of operations. Net income rose from HUF 133.5 M (FY2022) to HUF 171.1 M (FY2023), HUF 423.4 M (FY2024) and HUF 494.2 M (FY2025), then HUF 517.7 M in H1 2026 alone. Each step-up coincides with strong performance of Budapest bank equities; the company itself states that the positive financial result came mostly from unrealised gains on revaluing its liquid listed shares (mainly OTP). H1 2023's loss (HUF -24.8 M) shows the downside sensitivity when markets fall.

The cost base is rising in a non-cash way. SG&A rose from HUF 97.1 M to HUF 108.9 M in FY2025. Personnel expenses were HUF 72.9 M (FY2025) versus HUF 78.7 M (FY2024), with the company explaining that most of this relates to IFRS 2 share-based payment accruals under the remuneration policy that have not yet been paid out. Audit fees rose from HUF 3.0 M to HUF 11.4 M. In H1 2026, SG&A fell to HUF 80.8 M (from HUF 128.7 M in H1 2025), of which HUF 57.1 M was the MRP reserve increment. Cash running costs are therefore modest (perhaps HUF 30–50 M per year, derived), but the economic cost of the MRP — dilution of outside shareholders — is substantially larger than the P&L suggests.

Equity dynamics reflect capital-structure engineering. Equity fell from HUF 5,471.5 M (start of 2024) to HUF 4,955.9 M (end of 2024) despite HUF 423.4 M of profit, because of a HUF 671.9 M capital reduction (cancellation of the "G" voting-preference series) and HUF 342.0 M of treasury-share purchases. It then rose to HUF 5,519.6 M (FY2025) and HUF 6,094.3 M (H1 2026), driven by profits plus placements to the MRP.

Balance sheet is fortress-like but concentrated. Zero debt, liabilities under 1% of equity and a current ratio above 150x. However, at YE2025 roughly 40% of total assets were in a single stock (OTP), and roughly 31% of assets were in EUR/USD deposits creating FX volatility (FY2025 FX loss on revaluation was the main financial expense). Management's own sensitivity analysis shows a ±20% move in equities would change pre-tax profit by ±HUF 465.0 M — nearly equal to an entire year's net profit.

Tax. Effective tax rate ≈ 9.0% in FY2025 (HUF 48.9 M on HUF 543.0 M), equal to the Hungarian corporate tax rate; a deferred tax asset of HUF 16.1 M on share-based payment differences was not recognised.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Results by Segment and Revenue by Segment (%)

MetricFY2022FY2023FY2024FY2025

Single segment revenue (HUF Mn)

——0.450.45

Single segment operating result (HUF Mn)

——-97.1-112.0

Single segment pre-tax income (HUF Mn)

138.7177.9466.1543.0

Share of total revenue (%)

——100100

Group Entities

EntityRelationshipOwnershipFunctionKey data

NUTEX Befektetési Nyrt.

Parent, listed

—

Holding; IP leasing; capital allocation

Equity HUF 6,094 M (30 Jun 2026)

NT Asset Management Vagyonkezelő Kft.

Subsidiary

99.94% (minority: ITS GLOBAL Kft.)

Asset management (holding); holds the OTP shares since 31 Mar 2026

Registered capital HUF 5,218 M after Jul 2026

NT Valoris Akvizíciós és Vagyonkezelő Kft.

Sub-subsidiary

99.01% held by NT AM (minority: ITS GLOBAL Kft.)

Acquisition and asset-management vehicle

Founded 7 Jul 2026 with HUF 250 M; capital increased Aug and Oct 2026

NUTEX Nyrt. MRP Szervezet

Employee share ownership organisation

Founded by NUTEX; consolidated via IFRS "extension" method

Holds NUTEX shares for management incentive plans

41.1 M "E" shares, 23.96% (7 Jul 2026)

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025

Revenue (HUF Mn)

——0.450.45

Gross profit (HUF Mn)

——0.450.45

SG&A expenses (HUF Mn)

——97.1108.9

Operating income (HUF Mn)

——-97.1-112.0

EBITDA (HUF Mn, derived: operating result plus D&A)

——-97.0-111.7

Net financial result (HUF Mn)

——563.3655.0

Pre-tax income (HUF Mn)

138.7177.9466.1543.0

Income tax (HUF Mn)

——42.748.9

Net income (HUF Mn)

133.5171.1423.4494.2

EPS basic (HUF)

——2.843.80

EPS diluted (HUF)

——2.543.40

Dividends per share (HUF)

—000

Dividends & Capital Returns

MetricFY2024FY2025H1 2025H1 2026

Financial income total (HUF Mn)

563.3855.9342.0728.4

Dividends received (HUF Mn)

74.970.270.273.6

Interest received (HUF Mn)

3.318.213.51.0

Financial expenses total (HUF Mn)

0.0200.883.2129.9

of which unrealised FX losses (HUF Mn)

——83.294.2

Net financial result (HUF Mn)

563.3655.0258.8598.5

Income Statement and Per-Share Data (Half-Yearly)

MetricH1 2022H1 2023H1 2024H1 2025H1 2026

Net income (HUF Mn)

35.7-24.8267.9115.4517.7

Pre-tax income (HUF Mn)

———130.4517.9

Operating result (HUF Mn)

———-128.5-80.6

EPS basic (HUF)

———0.893.98

Balance Sheet

MetricFY2023FY2024FY2025

Total assets (HUF Mn)

5,480.34,998.45,555.3

Cash and equivalents (HUF Mn)

2,151.31,905.72,253.6

Short-term investments (HUF Mn)

—2,867.63,120.5

Other non-trade receivables (HUF Mn)

—224.2180.5

Short-term debt (HUF Mn)

000

Long-term debt (HUF Mn)

000

Net debt (HUF Mn, cash only)

-2,151.3-1,905.7-2,253.6

Total equity (HUF Mn)

5,471.54,955.95,519.6

Goodwill and intangibles (HUF Mn)

000

Current liabilities (HUF Mn)

—42.435.7

Working capital (HUF Mn)

—4,955.85,519.3

Asset Portfolio

AssetFY2025 value (HUF Mn)Share of total assets (%)Valuation level

Bank deposits and cash

2,253.640.6

Amortised cost

OTP Bank shares

2,248.140.5

Level 1

Erste Euro Real Estate Fund units

548.39.9

Level 2

Hungarian government securities

247.34.5

Level 2

Other receivables (incl. govt bond sale proceeds)

180.53.2

Amortised cost

MOL shares

57.51.0

Level 1

Richter shares

19.40.3

Level 1

Tangible assets and other

0.70.0

Cost

Total

5555.3

100.0

—

Cash Flow

MetricFY2024FY2025

Operating cash flow (HUF Mn)

-122.1256.3

Capex (HUF Mn)

-0.2-0.4

Free cash flow (HUF Mn, derived)

-122.3255.9

Dividends paid (HUF Mn)

00

Share buybacks (HUF Mn)

342.00

Net change in cash (HUF Mn)

-245.5347.8

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2023FY2024FY2025

ROE (%, derived, average equity)

—8.19.4

ROA (%, derived, average assets)

—8.19.4

Current ratio (x)

—117.8155.5

Debt to equity (x)

000

Liabilities to equity (%)

—0.860.65

Asset turnover (x, derived)

—0.00010.0001

Share Count (M)

MetricFY2024FY2025H1 2026

Shares outstanding incl. F series (M)

148.15158.45171.25

Book value per share (HUF, derived, parent equity / total shares)

33.534.835.6

Weighted avg shares basic (M)

149.0130.1—

Revenue by Region

RegionFY2024FY2025

Hungary (HUF Mn)

0.450.45

Rest of world (HUF Mn)

00

Segment Overview

SegmentHungary share (%)Other share (%)

Asset utilisation / IP leasing (single segment)

1000

Exposure Details

ExposureApprox. value (HUF Mn)Basis

Hungarian listed equities (OTP, MOL, Richter)

2,325.0

2025 Annual Report, Note 9

Hungarian government securities

247.3

2025 Annual Report, Note 9

EUR deposits

≈1451

Derived from ±10% EUR/HUF sensitivity of ±HUF 145.1 M

USD deposits

≈262

Derived from ±10% USD/HUF sensitivity of ±HUF 26.2 M

EUR real-estate fund (euro-area property)

548.3

2025 Annual Report, Note 9

HUF cash (residual, derived)

≈540

Total cash less derived FX deposits

Share Price History

DatePrice (HUF)ContextSource

Jun 2023

8 → 16

Graboplast speculation

Világgazdaság (Jan 2026 retrospective)

6 Dec 2024

17.8

Close before dividend proposal

Világgazdaság, Dec 2024

9 Dec 2024

22.9 intraday (+29%)

HUF 25 dividend proposal

Világgazdaság, Dec 2024

Dec 2024

up to 27

Peak of dividend speculation

Világgazdaság (Jan 2026 retrospective)

Jan 2025

24

Issue price of MRP placement

2025 Annual Report

26 Jan 2026

13.60 → 14.60

Retail speculation

Világgazdaság, Jan 2026

Jun 2026

13 → 13.7

Morvai stake disclosure

Világgazdaság, Jun 2026

21 Jun 2026

14.3

Issue price of MRP placement (≈ last close)

H1 2026 Report

23 Jul 2026

12.7—

Világgazdaság price widget

16 Oct 2026

12.4

Latest available

Világgazdaság price widget

Historic

12,200

All-time high (pre-restructuring basis)

Világgazdaság, 2017

Share Price & Returns

HorizonReturnBasis

Since Dec 2024 peak (HUF 27)

≈ -54% (derived)

Derived

Valuation Multiples

MultipleNUTEXBasis

Market cap (HUF Mn)

2,123

171.2 M listed shares × HUF 12.4

P/E (FY2025)

4.3x

Market cap / FY2025 net income HUF 494.2 M

P/E (TTM to Jun 2026)

2.4x

Market cap / TTM net income ≈ HUF 896.5 M

P/B

≈0.35x

Market cap / parent equity HUF 6,090.8 M (30 Jun 2026)

EV (HUF Mn)

≈ -205

Market cap less cash HUF 2,327.7 M (no debt); EV is negative even before counting the HUF 3.5 bn securities portfolio

Cash + securities per share (HUF, derived)

≈34.2

(2,327.7 + 3,535.5) / 171.25 M shares

Capital Markets

MetricFY2023FY2024FY2025

Dividend per share (HUF)

000

Dividends paid (HUF Mn)

—00

Capital Markets — FY2024 repurchase

ItemDetail

FY2024 repurchase

18 M shares for HUF 342 M (≈ HUF 19/share), subsequently transferred to MRP (Jan 2025)

Current authorisations

Up to 25% of share capital in treasury, 18-month term (granted 28 Apr, 28 May, 26 Jun 2026); price HUF 1 to 1.5x prior-year BVPS (ordinary) or up to 10x BVPS (preference shares); also call-option-based repurchases

Purchases since last AGM

None, per company disclosures at the May and June 2026 meetings

Credit Ratings

AgencyRating

Moody's

Not rated

S&P

Not rated

Fitch

Not rated

Analyst Conclusions

Management guidance

None provided. Management's only forward-looking statements concern the going-concern conclusion and the continued pursuit of acquisitions via NT Asset Management and NT Valoris.

Consensus expectations

No sell-side consensus exists. Mechanically, FY2026 earnings will be determined by year-end marks on OTP shares and the EUR/USD-to-HUF exchange rates; H1 2026 net income of HUF 517.7 M sets a high base.

Bull case

  1. Deep asset backing: cash plus liquid securities of ≈ HUF 34 per share (derived, 30 Jun 2026) versus a HUF 12.4 share price — even a substantial haircut to OTP still leaves a large margin of safety on paper.

  2. Transaction optionality: a fully built acquisition chain, HUF 60–70 bn authorisations and a new >5% holder with a healthcare background point to a potential transformative deal that could re-rate the shares, as seen in the Graboplast (2023) and dividend (2024) episodes when the price doubled or rose ~50%.

  3. Compounding NAV: four consecutive profitable years and record H1 2026 earnings (HUF 517.7 M) with negligible cash costs and no debt.

Bear case

  1. Minority value leakage: repeated below-book share issuance to a company-funded MRP (HUF 24, then HUF 14.3 per share), plus authorisation for ≥32 M more shares, transfers NAV per share from outside holders to insiders; the discount to NAV may be rational rather than an anomaly.

  2. Control entrenchment: MRP at 23.96%, deferred removal of voting caps, and authorised 10x-voting unlisted preference shares could make management effectively unremovable and decouple voting control from economic ownership.

  3. Concentrated, volatile NAV and regulatory overhang: ≈40% of assets in OTP and ≈31% in FX deposits; MNB fine and legality-supervision history; no assurance any acquisition will be accretive.

Key catalysts and monitorables (next 12 months)

Catalyst / monitorableWhy it matters
Announcement of a first acquisition via NT ValorisDetermines whether NUTEX becomes an operating company and at what dilution
Further MRP share acquisitions (≥32 M shares authorised)Dilution and control concentration
Any issuance of new 10x-voting preference sharesGovernance red flag
Decision on voting-cap removal (repeatedly deferred)Control dynamics
Outcome of the MNB-initiated Court of Registration proceedingRegulatory and governance risk
OTP share price and dividendsPrimary NAV and earnings driver
EUR/HUF and USD/HUF exchange ratesFX gains/losses on ≈ HUF 1.7 bn deposits
FY2026 Annual Report (expected late April 2027) and dividend decisionCash return to shareholders
Stance of significant shareholders (Morvai, historic holders) at general meetingsPotential resistance to, or support for, management proposals

Analyst verdict

NUTEX is best understood not as a pharmaceutical or consumer-health company — the label many data vendors still attach to it — but as a debt-free Hungarian investment shell whose roughly HUF 6.1 bn of assets consist almost entirely of bank deposits, OTP Bank shares, government paper and a euro real-estate fund. On a pure asset basis, the stock is strikingly cheap: at HUF 12.4 it trades at about 0.35x book value, below its cash balance alone, at roughly 2–4x earnings, with negative enterprise value.

The discount, however, is not a market inefficiency waiting to close by itself. The company's earnings are mark-to-market gains it does not distribute; it has declined to pay dividends for at least three consecutive years, including rejecting a shareholder-proposed HUF 25 per share payout in December 2024. Meanwhile, it has used company cash to fund an employee share ownership vehicle that has acquired nearly a quarter of the voting shares at prices well below book value, and shareholders have authorised capital increases of up to HUF 70 bn, further MRP accumulation and unlisted 10x-voting preference shares. The MNB has fined and warned the company and challenged the conduct of its December 2024 general meeting. For an outside investor, the critical question is therefore whose interests the eventual capital deployment will serve.

The most plausible paths are: (i) a large in-kind acquisition or reverse listing that transforms NUTEX, the value of which to current minorities will depend entirely on deal terms; or (ii) continued accumulation of NAV alongside incremental dilution. A shareholder-friendly outcome — a tender offer, large buyback or special dividend near NAV — is possible but not signalled.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenurePrior roles / other positionsCompensation (latest)

Gábor Sándor Csereklei

CEO (vezérigazgató); Board member (via CS Trade Kft. since 3 Jun 2025); Investor Relations

CEO start date not publicly disclosed

Managing director of CS Trade Kft.; managing-director representative of ITS GLOBAL Kft. at NT Asset Management Kft. and NT Valoris Kft.

Monthly gross salary HUF 266,800 to 31 Aug 2025; HUF 320,000 from 1 Sep 2025; HUF 322,800 in H1 2026. Annualised ≈ HUF 3.9 M (derived). Participant in MRP share-based plans (value not separately disclosed)

Board of Directors

MemberRoleSinceRepresented byIndependenceRemuneration

CS Trade Kft.

Board member

3 Jun 2025 (indefinite term)

Gábor Sándor Csereklei (managing director of CS Trade)

Executive / not independent

None for board role

RNT Holding Zrt.

Board member

3 Jun 2025 (indefinite term)

Szabolcs File (CEO of RNT Holding)

Listed as independent director (Investing.com shows File Szabolcs as independent since 2022)

None for board role

Dóra Kopros

Board member

——

Independent (per Investing.com)

None for board role

Viola Vargha

Board member

——

Independent (per Investing.com)

None for board role

Anikó Varghané Barta

Board member

——

Independent (per Investing.com)

None for board role

“—” = not publicly disclosed.

Governance Timeline

DateTransactionShares / amount

Nov–Dec 2024

NUTEX buys 18 M own shares (≈ HUF 19 each, HUF 342 M total)

18,000,000

15 Jan 2025

18 M treasury shares transferred to MRP

18,000,000

20 Jan 2025

Cash contribution from NUTEX to MRP

HUF 250 M

21 Jan 2025

Private placement to MRP at HUF 24/share

10,300,000 (HUF 247.2 M)

31 Dec 2025

MRP holding

28,300,000

18 Jun 2026

Cash contribution from NUTEX to MRP

HUF 265 M

21 Jun 2026

Private placement to MRP at HUF 14.3/share

12,800,000 (HUF 183.0 M)

7 Jul 2026

MRP holding

41,100,000 (23.96%)

28 May / 26 Jun 2026

AGM resolutions: fund MRP to acquire at least 32,000,000 further shares

≥32,000,000 (pending)

Board & Management Changes

DateChangeContext

3 Jun 2025

RNT Holding Zrt. (Szabolcs File) and CS Trade Kft. (Gábor Csereklei) elected to board

Conversion of individual board seats to legal-entity seats

1 Sep 2025

CEO salary raised from HUF 266,800 to HUF 320,000 per month

2025 Annual Report

2025–2026

Multiple amendments to remuneration policy (AGMs of 19 May 2025, 28 May 2026, 19 Jun 2026, 26 Jun 2026)

Expansion of MRP

25 Aug 2026

ITS GLOBAL Kft. (represented by Csereklei) appointed managing director of NT Valoris

Acquisition vehicle set-up

Major Shareholders

HolderStakeDate / sourceNotes

NUTEX Nyrt. MRP Szervezet

23.96% (41,100,000 shares)

7 Jul 2026, H1 2026 Report

Treated as treasury shares under IFRS extension method

Dr. László Morvai

5%

Jun 2026, Világgazdaság

Managing director of SOS Medical (Szeged-based GP and outpatient care provider)

Huber István

Not current; was >15% in 2017

Világgazdaság 2017; company offered to buy 10 M (+10 M option) of his shares in Nov 2024

Co-initiator of December 2024 EGM

Holba Sándor Imre

—

Co-initiator of December 2024 EGM (Világgazdaság)

—

Raltex Ltd.

—

Világgazdaság 2017

Historic largest holder

Remich Continental

—

Világgazdaság 2017

Historic

Galamb Vilmos

—

Világgazdaság 2017

Historic

“—” = not publicly disclosed.

Competitive Landscape

Key Competitors

CompanyTicker (BÉT)ProfileMarket cap (latest available)Relevance

ENEFI Vagyonkezelő Nyrt.

ENEFI

Small asset manager / thermal energy (Hungary, Cyprus, Romania)

≈ HUF 2.4 bn (Simply Wall St, undated)

Closest size peer; former operating company turned asset manager

Forrás Nyrt.

FORRAS

Small holding / asset management

—

Shell-like holding peer

OPUS GLOBAL Nyrt.

OPUS

Diversified holding (construction, industry, energy, tourism)

≈ HUF 255.4 bn (Simply Wall St, undated)

Large holding company benchmark

Budapesti Ingatlan Hasznosítási és Fejlesztési Nyrt. (BIF)

BIF

Real-estate holding

—

Asset-backed holding peer

Ormester Vagyonvédelmi Nyrt.

ORMESTER

Security services

≈ HUF 0.98 bn (Simply Wall St, undated)

Micro-cap Budapest peer

Budapest Stock Exchange (Budapesti Értéktőzsde)

BET

Exchange operator

≈ HUF 38.7 bn (Simply Wall St, undated)

Micro/small-cap Budapest reference

OTP Bank Nyrt.

OTP

Largest holding of NUTEX (≈40% of assets)

—

Primary NAV driver

MOL Nyrt.

MOL

Oil and gas; small NUTEX holding

≈ HUF 1.7–2.5 trn (Simply Wall St snapshots)

Portfolio holding

Gedeon Richter Nyrt.

RICHTER

Pharmaceuticals; small NUTEX holding; reference for NUTEX's former pharma identity

≈ HUF 2.2 trn (Simply Wall St, undated)

Portfolio holding / legacy sector benchmark

Nutex Health Inc. (US)

NASDAQ: NUTX

Unrelated US healthcare company

—

Name-confusion risk only

Peer Comparison FY2025

MetricNUTEX (FY2025)ENEFIOPUS GLOBAL

Revenue (HUF Mn)

0.45——

Revenue growth (%)

0——

Net income (HUF Mn)

494.2——

Market cap (HUF Bn)

≈2.1

≈2.4

≈255.4

R&D intensity (%)

0——

Company Snapshot

1

Employees

1996

Founded

SWOT Analysis

Strengths

  • Zero financial debt: no short- or long-term borrowings at YE2023, YE2024, YE2025 or 30 Jun 2026; long-term debt fully repaid in prior years (2025 Annual Report).
  • Exceptional liquidity: current ratio 155.5x at YE2025 and ≈645x at 30 Jun 2026 (current assets HUF 6,103 M vs current liabilities HUF 9.5 M).
  • Large cash pile relative to market value: cash alone (HUF 2,327.7 M at 30 Jun 2026) exceeds the entire market capitalisation (≈ HUF 2,123 M at HUF 12.4).
  • Consistent profitability over four reported years: net income HUF 133.5 M (FY2022), 171.1 M (FY2023), 423.4 M (FY2024), 494.2 M (FY2025).
  • Very low cash overhead: CEO salary ≈ HUF 3.9 M per year (annualised from HUF 322,800/month); board serves unpaid; rent HUF 2.1 M (FY2025).
  • Pre-approved capital flexibility: board authorised to raise capital by up to HUF 60–70 bn until 2031 (AGM/EGMs April–June 2026), enabling rapid execution of a large transaction.
  • Ready-built acquisition structure: NT Asset Management (HUF 5,218 M capital) and NT Valoris (founded July 2026) in place.

Weaknesses

  • No operating business: revenue of HUF 0.45 M (FY2025), 100% from one counterparty.
  • Earnings quality: profits are predominantly unrealised fair-value gains (HUF 728.4 M fair-value income in H1 2026) rather than cash earnings; operating result negative every year (HUF -112.0 M FY2025).
  • Asset concentration: OTP shares ≈ 40.5% of total assets at YE2025 (HUF 2,248.1 M of HUF 5,555.3 M).
  • FX volatility: EUR and USD deposits of ≈ HUF 1.7 bn (derived) generated HUF 94.2 M unrealised FX losses in H1 2026.
  • Rising non-cash cost base: share-based payment reserve rose from HUF 74.9 M (YE2024) to HUF 197.9 M (30 Jun 2026).
  • Thin governance resources: single executive, outsourced accounting, no diversity policy, legal-entity directors (2025 Annual Report; H1 2026 Report).
  • Inconsistencies in disclosures: e.g., two different 2024 weighted-average share counts (149.0 M vs 146.0 M) and a share-count/nominal table in the H1 2026 report labelled with the wrong date — minor, but indicative of limited reporting resources.

Opportunities

  • Reverse-listing / transformative deal: financial press repeatedly highlights NUTEX's potential as a shell for a company seeking a listing; authorisations up to HUF 70 bn allow a deal many times current size.
  • NAV discount closure: shares at ≈0.35x book value (HUF 12.4 vs ≈HUF 35.6 derived BVPS at 30 Jun 2026); buybacks, a tender offer, liquidation or a special dividend could unlock value.
  • Healthcare angle: Dr. László Morvai (SOS Medical) crossed 5% in June 2026; a healthcare-related transaction would reconnect with the company's Humet heritage (speculative).
  • Dividend capacity: distributable reserves (retained earnings HUF 4,986.7 M at 30 Jun 2026) could support distributions; a HUF 25/share proposal was already tabled once (Dec 2024).
  • Continued strength in OTP: further gains in OTP and dividends (HUF 73.6 M received in H1 2026) would compound NAV.
  • Interest-rate/yield redeployment: HUF 2.3 bn of cash could earn meaningfully higher yields if allocated to government securities again (interest income was only HUF 1.0 M in H1 2026).

Threats

  • Dilution of minority shareholders: MRP placements at HUF 24 (Jan 2025) and HUF 14.3 (Jun 2026) versus ≈HUF 35 BVPS, with authorisation for ≥32 M more shares.
  • Voting control concentration: MRP at 23.96%; new unlisted voting-preference shares with up to 10x votes authorised (26 Jun 2026); voting-cap removal repeatedly deferred.
  • Regulatory scrutiny: MNB legality-supervision proceeding (2025) over the December 2024 EGM, and HUF 4 M fine plus warning (27 Nov 2025).
  • Market drawdown: management's own sensitivity analysis shows a ±20% equity move changes pre-tax profit by ±HUF 465.0 M (FY2025).
  • Value-destructive acquisition risk: an acquisition priced via in-kind contribution could transfer value from minorities; the 2023 Graboplast proposal was rejected by shareholders.
  • Liquidity/speculation risk: thin trading means prices can move 5–30% on rumours (e.g., +29% intraday in Dec 2024; +5–7% in Jan and Jun 2026).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
8 May 2025Court registers NT AM changes (ITS GLOBAL minority, legal-entity MD)Subsidiary governance set-up
12 May 2025First-instance court terminates shareholder lawsuit seeking annulment of 29 Dec 2024 EGM resolutionsLegal risk reduced
19 May 2025Continued AGM approves amended Remuneration PolicyMRP framework
3 Jun 2025RNT Holding Zrt. and CS Trade Kft. elected to boardBoard reconstitution
13 Jun 2025Plaintiff appeals the lawsuit terminationLegal risk re-opened
1 Sep 2025CEO monthly salary raised to HUF 320,000Remuneration
Late Sep 2025H1 2025 report: net profit HUF 115.4 M vs HUF 267.9 M in H1 2024Earnings volatility
18 Nov 2025Budapest Court of Appeal finally upholds termination of lawsuitLitigation closed
27 Nov 2025MNB warning and HUF 4 M fine (H-PJ-III-B-28/2025)Regulatory/reputational
5 Dec 2025HUF 1,747 M cash injection into NT AMRestructuring toward acquisition holding
15 Dec 2025NT AM capital increase registered (HUF 2,050 M; 99.85%)—
26 Jan 2026Shares jump ~5–7% intraday (HUF 13.60→14.60) on retail speculation about OTP/MOL holdings and discount to bookIllustrates thin, speculative trading
31 Mar 2026OTP shares transferred OTC to NT AMAssets moved down the chain
2 Apr 2026HUF 1,845 M injection into NT AM (capital HUF 3,895 M)—
13 Apr 2026NT AM capital increase registered (99.92%)—
20 Apr 2026EGM decides not to pay a dividend at presentCapital retained
28 Apr 2026AGM approves FY2025 accounts (net profit HUF 494.2 M), no dividend; HUF 60 bn capital authorisation; treasury-share authorisations; FY2025 annual report publishedKey filing
20 May 2026Continued EGM: further HUF 60 bn authorisations (to 2031 and 2031–2036); support for transferring fund units to NT AM; voting-cap decision deferredCapital flexibility
28 May 2026Continued AGM: HUF 70 bn authorisation; MRP to acquire ≥32 M more shares; remuneration policy amendedDilution potential
Jun 2026Dr. László Morvai crosses 5%; shares rise ~5% (HUF 13→13.7)New significant shareholder
18 Jun 2026HUF 265 M cash contribution to MRPMRP funding
19 Jun 2026Continued EGM: HUF 65 bn authorisation; MRP placement mandate; new acquisition Kft. structure approved—
21 Jun 2026Board resolves 12.8 M share placement to MRP at HUF 14.3Below-book issuance
26 Jun 2026Court registers articles changes and capital increase; continued AGM approves new voting-preference share programme and further authorisationsGovernance concentration
2 Jul 2026HUF 1,323 M injection into NT AM (capital HUF 5,218 M; 99.94%)—
7 Jul 2026New shares listed; MRP reaches 41.1 M shares (23.96%); NT Valoris Kft. founded—
9 Jul 2026NT Valoris registered—
25 Aug 2026ITS GLOBAL enters NT Valoris (99.01% NT AM); ITS GLOBAL/Csereklei appointed MD; articles amendment (effective 1 Aug 2026) registered—
1 Sep 2026NT Valoris changes registered; voting-rights notice—
30 Sep 2026H1 2026 report: net profit HUF 517.7 M; equity HUF 6,094 MRecord half-year
13 Oct 2026Announcement of further NT Valoris capital increase by NT AMAcquisition preparation continues

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Income Statement: Revenue & Gross Profit: Revenue held from HUF 0.5 Mn in FY2024 to HUF 0.5 Mn in FY2025.
NUTEX Investments Public Limited Company — Income Statement: Revenue & Gross Profit
Series (HUF Mn)FY2024FY2025
Revenue0.50.5
Gross profit0.50.5

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.